New Delhi, July 04, 2020: The Delhi High Court today enjoined the National Pharmaceutical Pricing Authority (NPPA) from taking any coercive steps against Glenmark Pharmaceuticals Ltd pursuant to its Notification dated 03.03.2020 and Order dated 20.03.2020, wherein NPPA had fixed the retail price of the new drug being "Remo M" and "RemoZen M" containing Remogliflozin Etabonate + Metformin Hydrochloride (100mg + 500 mg and 100mg + 1000mg) ('subject formulation').

The Delhi High Court vide its Order dated 29.01.2020 passed in W.P (C)1075/2020 had directed National Pharmaceutical Pricing Authority (NPPA) to grant a personal hearing to Glenmark Pharmaceutical Ltd and subsequently pass a reasoned order on whether the subject formulation is exempt from price control under paragraph 32 (i) of the Drugs Price Control Order, 2013 ('DPCO, 2013'). However, National Pharmaceutical Pricing Authority (NPPA) failed to consider the submissions made by Glenmark Pharmaceutical Ltd and notified the retail price of the subject formulation.

Aggrieved by the said Notification and Order that the Glenmark Pharmaceutical Ltd was constrained to seek protection from Delhi High Court and the present Writ Petition stems from an earlier writ petition filed by Glenmark Pharmaceuticals Ltd in the beginning of this year.

Mr. Arvind K. Nigam, Senior Advocate, assisted by Advocates from Karanjawala & Co.- Mr. Debmalya Banerjee-Partner, Mr. Rohan Sharma-Principal Associate, Mr. Kartik Bhatnagar-Principal Associate, Dheeraj P.Deo-Associate & Mr. Vardaan Wanchoo-Associate along with Mr. Abhay Jadeja & Partners and Ms. Shruti Katakey-Partner from Crawford Bayley & Co. was represented by the Glenmark Pharmaceutical Ltd.

The Respondents were represented by Mr. Kirtiman Singh from the National Pharmaceutical Pricing Authority (NPPA).

News Courtesy:PIB | Hindu| DC | LE | LI | LO | IE | LL | PTI |ht | ET | UNI | DNA | FP | Jurist |IndToday|

Disclaimer: Information, facts or opinions expressed in this news article are presented as sourced supplied by the concerned either as press release, press statement or via other source of information, websearch engines and internet and do not reflect views of Lawtime and hence Lawtime is not responsible or liable for the same. As a source and news provider, India info Comm Network's website Lawtime.in is not responsible for any of the copy right violation or for accuracy, completeness, suitability and validity of any information in this news article

Comments

Name*:
Phone number:
Email address*:
Comments and questions*:
Enter web form code*: reload image * - required fields.